MTS1及E-cadherin的表达与乳腺癌转移的关系

Relationship between Expression of Multiple Tumor Suppressor(MTS1) and E-cadherin and Metastasis of Breast Carcinoma

背景与目的:乳腺癌患者主要死于远处转移,目前还没有一种预测和早期诊断乳腺癌转移的方法。本研究旨在观察多肿瘤抑制基因(multipletumorsuppressor1,MTS1/p16)及上皮型钙粘附素(E-cadherin)的表达与乳腺癌转移的关系。方法:应用免疫组化S-P法,检测54例乳腺癌组织中的MTS1、E-cadherin的表达。结果:MTS1在远处转移组和多于4枚局部淋巴结转移组的表达率(分别为40.7%、38.1%)均低于相应对照组(74.1%、69.7%)(P<0.05);在组织学分级Ⅰ、Ⅱ、Ⅲ级三组中的表达率分别为76.2%、58.8%、31.3%,三组间差异有显著性(P<0.01)。E-cadherin在远处转移组和多于4枚局部淋巴结转移组的表达率(分别为37%、23.8%)均低于相应对照组(70.4%、66.7%)(P<0.05);在组织学分级Ⅰ、Ⅱ、Ⅲ级三组中的表达率分别为80.9%、47.1%、25.0%,三组间差异有显著性(P<0.01)。结论:MTS1及E-cadherin与乳腺癌的浸润和转移相关。

BACKGROUND &OBJECTIVE: Most of breast cancer patients died of distant metastasis. There is still not a method of predicting and early diagnosing the metastasis. This study was conducted to investigate the relationship between the expression of multiple tumor suppressor 1(MTS1) as well as E cadherin and metastasis in breast cancer. METHODS: The expression of MTS1 and E cadherin were detected by SP immunohistochemical technique in 54 paraffin embedded tissue specimens of breast cancer. RESULTS: The positive rates of MTS1 in the distant metastasis group and more than 4 local lymph node metastasis group were 40.7%and 38.1%, respectively, which were lower than individual corresponding control groups (74.1%and 69.7%)(P< 0.05). The MTS1 expression rates in the three groups of pathology grade Ⅰ, Ⅱ, and Ⅲwere 72.6%, 58.8%, and 31.3%, respectively, with significant differences (P< 0.05). The positive rates of E cadherin in the distant metastasis group and more than 4 local lymph node metastasis group were 37%and 23.8%, respectively, which are lower than individual corresponding control groups (70.4%and 66.7%)(P< 0.05). The E cadherin expression rates in the three groups of pathology grade Ⅰ, Ⅱ, Ⅲwere 80.9%, 47.1%,and 25%, respectively, with significant differences (P< 0.01). CONCLUSION: There was a close relation between MTS1, E cadherin and invasion, metastasis of breast cancer. They can be used as the biological markers for evaluating the latent metastasis, disease development, and prognosis in breast cancer.